Polarean Imaging plc
01/24/2025 | Press release | Archived content
Block Listing Six Monthly Return
Corporate News
Block Listing Six Monthly Return
24 January 2025
Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | Polarean Imaging Plc | ||||
| Name of scheme: | Polarean Share Option Plan | ||||
| Number and class of securities originally admitted: | 8,000,000 ordinary shares of £0.00037 each | ||||
| Date of admission: | 29 July 2021 | ||||
| Period of return: | From: | 27 July 2024 | To: | 24 January 2025 | |
| Balance of unallotted securities under scheme(s) from previous return: | 808,917 | ||||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | ||||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
0 |
||||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 808,917 | ||||
| Total number of securities in issue at the end of the period | 1,207,032,781 | ||||
| Name of contact: | Charles F. Osborne, Jr., Chief Financial Officer |
| Telephone number of contact: | + 44 (0)20 7933 8780 or [email protected] |
Enquiries:
| Polarean Imaging plc | https://www.polarean.com / https://www.polarean-ir.com | ||||
| Christopher von Jako, Chief Executive Officer | Via Walbrook PR | ||||
| Charles Osborne, Chief Financial Officer | |||||
| Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | ||||
| Nicholas Moore / Nick Harland / Ben Good | |||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | ||||
| Anna Dunphy /Phillip Marriage | Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 | ||||
About Polarean (https://www.polarean.com)
Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit https://www.polarean.com
« back to Corporate News
Latest News
-
Holding(s) in Company
11 September 2025 -
Submission of new Phase III study protocol to FDA for expanded indication of XENOVIEW
12 August 2025 -
Block Listing Six Monthly Return
24 July 2025
Corporate News
View About us
About Us
Share Price
Share Price
-
GBp
-
-
-
Annual Report & Account 2024 (inc. Notice of AGM)
Latest Annual Report
Important Dates
Important dates
09 Jun
Annual General Meeting
08 May
Final Results
Investor Alert
Sign up for Email Alerts
Investor Alert
Polarean Imaging plc published this content on January 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 15, 2025 at 10:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]